Teva And mAbxience Expand Strategic Partnership To Include An Additional Oncology Biosimilar Candidate; Both Companies Reaffirm Their Shared Commitment To Making High-Quality, Affordable Treatments Accessible To Patients Worldwide
Portfolio Pulse from Benzinga Newsdesk
Teva Pharmaceuticals and mAbxience have expanded their strategic partnership to include a new oncology biosimilar candidate. This collaboration supports Teva's growth strategy and aims to provide affordable, high-quality treatments globally.
October 03, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Teva Pharmaceuticals has expanded its partnership with mAbxience to develop a new oncology biosimilar, aligning with its Pivot to Growth strategy. This move strengthens Teva's biosimilar portfolio and supports its goal of providing affordable treatments.
The expansion of the partnership with mAbxience to include a new oncology biosimilar aligns with Teva's strategic goals and enhances its product offerings. This is likely to positively impact Teva's stock as it strengthens its position in the biosimilar market.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90